Treatment of Symptomatic Bilateral Knee Osteoarthritis: Intra-articular Injection of Autologous Microfragmented Adipose Tissue and Hyaluronic Acid vs Intra Articular Injection of Autologous Microfragmented Adipose Tissue

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-75
SponsorIstituto Ortopedico Rizzoli

About this trial

The HYALOFAT study is a randomized controlled double-blind trial with parallel treatment arms and 1:1 allocation.

By means of a double-blind randomized controlled trial in patients with symptomatic bilateral OA of the knees, the clinical outcomes of autologous microfragmented adipose tissue injection associated with hyaluronic acid in one knee vs autologous microfragmented adipose tissue injection in the contralateral knee will be evaluated and compared. Each patient will then serve as his or her own control and not be informed of the knee assigned to the treatment group. In addition, it will be the aim of the study to evaluate the safety of the combined treatment by documenting any adverse events.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Male or female patients aged between 18 and 75;

Radiographic evidence of bilateral OA of the knees graded between 2 and 4 on the Kellgren-Lawrence scale;

Pain equal to or greater than 4 on the Numeric Rating Scale (NRS) for both knees;

Failure, defined as persistence of symptoms after at least 6 months of conservative treatment (pharmacological, physiotherapy, or infiltration treatment);

Disqualifiers

Patients incapable of understanding and willing;

Diagnosis of active neoplasia;

Diagnosis of rheumatoid arthritis, Reiter's syndrome, psoriatic arthritis, gout, ankylosing spondylitis, or arthritis resulting from another inflammatory disease; human immunodeficiency virus (HIV) infection, active viral hepatitis; chondrocalcinosis;

Patients with uncontrolled diabetes mellitus;

Trial design

Design model

Parallel

Treatments tested in this trial

  • MFAT + HA left knee - MFAT + placebo right knee

    Device

    The left knee will be treated with an injection of high-molecular-weight hyaluronic acid (4 cc) and microfragmented autologous adipose tissue (6 cc), harvested from the abdominal site.The right knee will be treated with microfragmented autologous adipose tissue (6 cc), also harvested from the abdominal site by liposuction and microfragmentation, combined with an injection of 4 cc of saline (NaCl 0.9%)

  • MFAT + HA right knee - MFAT + placebo left knee

    Biological/Vaccine

    The right knee will be treated with an injection of high-molecular-weight hyaluronic acid (4 cc) and microfragmented autologous adipose tissue (6 cc), harvested from the abdominal site.The left knee will be treated with microfragmented autologous adipose tissue (6 cc), also harvested from the abdominal site by liposuction and microfragmentation, combined with an injection of 4 cc of saline (NaCl 0.9%)

Treatment groups

100 Participants
are divided into 2 treatment groups
Group A: MFAT + HA left knee - MFAT + placebo right kneeExperimental treatment 1 intervention
Group B: MFAT + HA right knee - MFAT + placebo left kneeActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)

It's a standardized and widely used questionnaire to assess the condition of patients with osteoarthritis of the knee and includes assessment of pain, stiffness, and physical function of the joints. It can be administered to the patient. It measures 5 items for pain (range 0-20), two for stiffness (range 0-8), and 17 for functional limitation (range 0-68) that mainly relate to activities of daily living (e.g., getting up from a sitting position, bending over, going up and down stairs etc.); The score is then normalized on a 0-100 scale. Higher values indicate a worse outcome

Time frame
12 months

Secondary outcomes

1

Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)

It's a standardized and widely used questionnaire to assess the condition of patients with osteoarthritis of the knee and includes assessment of pain, stiffness, and physical function of the joints. It can be administered to the patient. It measures 5 items for pain (range 0-20), two for stiffness (range 0-8), and 17 for functional limitation (range 0-68) that mainly relate to activities of daily living (e.g., getting up from a sitting position, bending over, going up and down stairs etc.); The score is then normalized on a 0-100 scale. Higher values indicate a worse outcome

Time frame
baseline, 2,6,24 months
2

IKDC-Subjective Score

This is a subjective, knee-specific rating scale that is considered one of the most reliable assessment tools in the evaluation of knee pathologies. All questions examines 3 categories: symptoms, sports activity, and knee function.

Time frame
baseline, 2,6,12,24 months
3

IKDC-Objective Score (Objective International Knee Documentation Committee)

The objective assessment scale has seven parameters related to knee function. The presence of effusion and degree of knee movement are assessed, with the worst value of one of these parameters determining the final IKDC grade. There are four grades (A, B, C, D) which identify a knee assessed as normal, near normal, abnormal, and severely abnormal, respectively.

Time frame
baseline, 2,6,12,24 months
4

Patient Acceptable Symptom State (PASS)

A tool to assess patient satisfaction in consideration of their current degree of pain, function, and daily activity. Patients can express if their state of health will be satisfying, answering "yes" or "no.

Time frame
baseline, 2,6,12,24 months

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.